Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics

American Journal of Ophthalmology
Rookaya MatherR P Kowalski

Abstract

Fourth generation fluoroquinolones (FQs) will soon be introduced to ophthalmology. In this in vitro study, differences in the susceptibility patterns and the potencies of fourth generation FQs (gatifloxacin-GAT and moxifloxacin-MOX) were compared with third generation (levofloxacin-LEV) and second generation FQs (ciprofloxacin-CIP and ofloxacin-OFX). Experimental laboratory investigation. In retrospect, the minimum inhibitory concentrations (MICs) of 93 bacterial endophthalmitis isolates were determined to CIP, OFX, LEV, GAT, and MOX using E-tests. The National Committee of Clinical Laboratory Standards (NCCLS) susceptibility patterns and the potencies of the MICs were statistically compared. With in vitro tests, Staphylococcus aureus isolates that were resistant to CIP and OFX were statistically most susceptible (P =.01) to MOX. Coagulase negative Staphylococci that were resistant to CIP and OFX were statistically most susceptible (P =.02) to MOX and GAT. Streptococcus viridans were more susceptible (P =.02) to MOX, GAT, and LEV than CIP and OFX. Streptococcus pneumoniae was least susceptible (P =.01) to OFX compared with the other FQs. Susceptibilities were equivalent (P =.11) for all other bacterial groups. In general, MOX w...Continue Reading

Associated Clinical Trials

Dec 26, 2019·Wan Haslina Wan Abdul Halim

References

Jul 16, 1999·Ophthalmology·M H GoldsteinY J Gordon
Dec 20, 1999·Drugs·R Stahlmann, H Lode
Nov 30, 1999·American Journal of Ophthalmology·N A ChaudhryD Miller

❮ Previous
Next ❯

Citations

Mar 11, 2005·Expert Review of Anti-infective Therapy·Regis P Kowalski, Deepinder K Dhaliwal
Jan 15, 2014·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Takahiro UdaYuichi Ohashi
Sep 17, 2009·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·M KerntA Kampik
Dec 13, 2006·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·M J KossH M de Kaspar
Sep 23, 2014·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Warren HellerHarold Jensen
Dec 4, 2014·Journal of Cataract and Refractive Surgery·Rosa Braga-MeleUNKNOWN ASCRS Clinical Cataract Committee
Sep 26, 2003·The British Journal of Ophthalmology·J A Lomholt, M Kilian
May 25, 2004·Antimicrobial Agents and Chemotherapy·Joseph J DajcsRichard J O'Callaghan
Apr 19, 2005·The British Journal of Ophthalmology·G KampougerisH Giamarellou
Nov 10, 2009·Clinical Ophthalmology·Koji SugiokaYoshikazu Shimomura
May 17, 2011·Clinical Ophthalmology·Lorenzo J Cervantes, Francis S Mah
Oct 22, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Kristin A RareyRegis P Kowalski
Sep 26, 2012·Molecular Pharmaceutics·Sunil K VooturiUday B Kompella
Dec 24, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Soon-Phaik Chee
Aug 29, 2012·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Regis P KowalskiFrancis S Mah
Dec 20, 2012·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Yoshitaka TasakaYuichi Ohashi
Jul 4, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Kazuki MatsuuraYoshitsugu Inoue
Oct 7, 2006·Current Medical Research and Opinion·Kendall E DonaldsonEduardo C Alfonso
Oct 27, 2015·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Regis P KowalskiFrancis S Mah
May 17, 2011·Expert Review of Ophthalmology·Billy D Novosad, Michelle C Callegan
Jul 23, 2013·Journal of Investigative Surgery : the Official Journal of the Academy of Surgical Research·Lorenzo ZaffiriLuis H Toledo-Pereyra
May 10, 2013·Current Eye Research·Bianka SobolewskaEfdal Yoeruek
Sep 1, 2007·Clinical & Experimental Ophthalmology·Andrew M Thompson
Oct 11, 2014·BioMed Research International·Rohit ShettyRajesh S Kumar
May 15, 2013·Ophthalmic Epidemiology·Catherine E OldenburgNisha R Acharya
Nov 6, 2004·BMC Bioinformatics·Julien Gagneur, Steffen Klamt
May 24, 2016·Journal of Ophthalmology·S MarasiniJ P Craig
Dec 22, 2006·Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde·Guy KleinmannRandall J Olson
Jul 6, 2004·American Journal of Ophthalmology·Regis P KowalskiY Jerold Gordon
Aug 12, 2016·Clinical and Translational Imaging : Reviews in Nuclear Medicine and Molecular Imaging·S AulettaAlberto Signore
Aug 4, 2004·American Journal of Ophthalmology·Michelle K RheeY Jerold Gordon
Mar 19, 2004·Survey of Ophthalmology·Joseph M Blondeau
Aug 25, 2016·International Journal of Antimicrobial Agents·Andreana MarinoGiuseppe Bisignano
Apr 25, 2006·Journal of Cataract and Refractive Surgery·Majid MoshirfarPaul C Kang
Aug 18, 2005·Journal of Cataract and Refractive Surgery·Melvin A SaraybaPeter J McDonnell
Nov 1, 2005·Survey of Ophthalmology·Eduardo Alfonso, Julie Crider

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.